Literature DB >> 24729930

Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Edward C Oldfield1, Edward C Oldfield1, David A Johnson1.   

Abstract

Clostridium difficile infection (CDI) presents a rapidly evolving challenge in the battle against hospital-acquired infections. Recent advances in CDI diagnosis and management include rapid changes in diagnostic approach with the introduction of newer tests, such as detection of glutamate dehydrogenase in stool and polymerase chain reaction to detect the gene for toxin production, which will soon revolutionize the diagnostic approach to CDI. New medications and multiple medical society guidelines have introduced changing concepts in the definitions of severity of CDI and the choice of therapeutic agents, while rapid expansion of data on the efficacy of fecal microbiota transplantation heralds a revolutionary change in the management of patients suffering multiple relapses of CDI. Through a comprehensive review of current medical literature, this article aims to offer an intensive review of the current state of CDI diagnosis, discuss the strengths and limitations of available laboratory tests, compare both current and future treatments options and offer recommendations for best practice strategies.

Entities:  

Keywords:  Antibiotic-associated diarrhea; Clostridium difficile; Fecal transplantation; Fidaxomicin; Probiotics; Rifaximin

Year:  2014        PMID: 24729930      PMCID: PMC3951810          DOI: 10.4292/wjgpt.v5.i1.1

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  207 in total

1.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 2.  Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

Authors:  Alan P Johnson
Journal:  Curr Opin Investig Drugs       Date:  2007-02

Review 3.  Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection.

Authors:  M H Wilcox
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

4.  In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.

Authors:  T Peláez; L Alcalá; R Alonso; A Martín-López; V García-Arias; M Marín; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

6.  Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

Authors:  Simon D Baines; Katie Saxton; Jane Freeman; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2006-10-08       Impact factor: 5.790

7.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection.

Authors:  Elizabeth J Kvach; David Ferguson; Paul F Riska; Marie L Landry
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

10.  Numbers and strains of lactobacilli in some probiotic products.

Authors:  Valérie Coeuret; Micheline Gueguen; Jean Paul Vernoux
Journal:  Int J Food Microbiol       Date:  2004-12-15       Impact factor: 5.277

View more
  23 in total

1.  A small-molecule antivirulence agent for treating Clostridium difficile infection.

Authors:  Kristina Oresic Bender; Megan Garland; Jessica A Ferreyra; Andrew J Hryckowian; Matthew A Child; Aaron W Puri; David E Solow-Cordero; Steven K Higginbottom; Ehud Segal; Niaz Banaei; Aimee Shen; Justin L Sonnenburg; Matthew Bogyo
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

2.  A new role for heat shock factor 27 in the pathophysiology of Clostridium difficile toxin B.

Authors:  Murali K Yanda; William B Guggino; Liudmila Cebotaru
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

3.  The (p)ppGpp Synthetase RSH Mediates Stationary-Phase Onset and Antibiotic Stress Survival in Clostridioides difficile.

Authors:  Astha Pokhrel; Asia Poudel; Kory B Castro; Michael J Celestine; Adenrele Oludiran; Alden J Rinehold; Anthony M Resek; Mariam A Mhanna; Erin B Purcell
Journal:  J Bacteriol       Date:  2020-09-08       Impact factor: 3.490

Review 4.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.

Authors:  Patrizia Spigaglia
Journal:  Ther Adv Infect Dis       Date:  2016-02

Review 5.  Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.

Authors:  Fawziah Marra; Karen Ng
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 6.  Battling Enteropathogenic Clostridia: Phage Therapy for Clostridioides difficile and Clostridium perfringens.

Authors:  Jennifer Venhorst; Jos M B M van der Vossen; Valeria Agamennone
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

Review 7.  Microbiome Changes during Tuberculosis and Antituberculous Therapy.

Authors:  Bo-Young Hong; Nancy Paula Maulén; Alexander J Adami; Hector Granados; María Elvira Balcells; Jorge Cervantes
Journal:  Clin Microbiol Rev       Date:  2016-09-08       Impact factor: 26.132

8.  A High Rate of Alternative Diagnoses in Patients Referred for Presumed Clostridium difficile Infection.

Authors:  Melissa Jackson; Sidney Olefson; Jason T Machan; Colleen R Kelly
Journal:  J Clin Gastroenterol       Date:  2016-10       Impact factor: 3.062

9.  Method comparison for the direct enumeration of bacterial species using a chemostat model of the human colon.

Authors:  Ines B Moura; Charmaine Normington; Duncan Ewin; Emma Clark; Mark H Wilcox; Anthony M Buckley; Caroline H Chilton
Journal:  BMC Microbiol       Date:  2020-01-02       Impact factor: 3.605

10.  Clostridium difficile fecal toxin level is associated with disease severity and prognosis.

Authors:  Nathaniel A Cohen; Tamar Miller; Wasef Na'aminh; Keren Hod; Amos Adler; Daniel Cohen; Hanan Guzner-Gur; Erwin Santo; Zamir Halpern; Yehuda Carmeli; Nitsan Maharshak
Journal:  United European Gastroenterol J       Date:  2017-12-21       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.